Halop5 mg

In low doses- nervousness, anxiety states and associated psychic disorders as irritability gressiveness, psychic lability and insomnia functional disorders caused by anxiety states such as trembling, thorax oppression, gastrointestinal hypermotility and digestive disorders tics and stuttering ... Read moreIn low doses- nervousness, anxiety states and associated psychic disorders as irritability gressiveness, psychic lability and insomnia functional disorders caused by anxiety states such as trembling, thorax oppression, gastrointestinal hypermotility and digestive disorders tics and stuttering nausea and vomiting In higher doses- psychomotor agitation in mania, dementia, acute and chronic schizophrenia, alcoholism delusions and hallucinations in acute and chronic schizophrenia, acute confusion choreatic movements behavior and character disorders in children tics and stuttering vomiting

Butyrophenone drugs, Drugs used in tremor, tics & related disorder

Halop 5 mg blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system and decreases the release of hypothalamic and hypophyseal hormones. It produces calmness and reduces aggressiveness with disappearance of hallucinations and delusions.

Tablet-Initial dose for adults- Moderate symptomatology: 0.5 mg to 3.0 mg 2 to 3 times daily Severe symptomatology: 3.0 mg to 5.0 mg 2 to 3 times daily Elderly patients: 0.5 mg to 4.5 mg 2 to 3 times daily Chronic or Resistant patients: 3.0 mg to 6.0 mg 2 to 3 times daily Patients who remain severely disturbed or inadequately controlled may require dose adjustment. Daily dose upto 100 mg may be necessary in some cases to achieve optimal response. Children: A suggested dose for the management of behaviour disorders in disturbed and schizophrenic children is 50 microgram per kg body weight.Injection (intramuscular or intravenous)-Schizophrenia and other psychosis, mania: Initially 2-10 mg, then every 4-8 hours according to response to total maximum 18 mg daily Severely disturbed patients may require an initial dose of up to 18 mg Elderly (or debilitated) initially half adult dose For children not recommended.

Dosage for all indications should be individually determined and is best initiated and titrated under close clinical supervision. To determine the initial dose consideration should be given to the patients age, severity of symptoms and previous response to other neuroleptics. The normal starting dose should be halved, followed by a gradual titration to achieve an optimal response.

Halop 5 mg has been reported to interfere with the anticoagulant properties of phenindione in an isolated case and the possibility should be kept in mind of a similar effect occurring when Halop 5 mg is used with other anticoagulants. Halop 5 mg may antagonize the action of epinephrine and other sympathomimetic agents and reverse the blood pressure lowering effects of adrenergic-blocking agents, such as guanethidine. Enhanced CNS effects may occur when Halop 5 mg is used in combination with methyldopa. Halop 5 mg inhibits the metabolization of tricyclic antidepressants, thereby increasing plasma levels of these drugs. This may result in increased tricyclic antidepressant toxicity (anticholinergic effects, cardiovascular toxicity, lowering of seizure threshold). Halop 5 mg may impair the antiparkinson effects of levodopa. If an antiparkinson agent is used concomitantly with Halop 5 mg, both drugs should not be discontinued simultaneously, since extrapyramidal symptoms may occur due to the slower excretion rate of Halop 5 mg.

Comatose states and CNS depression due to alcohol or other depressant drugs; severe depressive states; previous spastic diseases; lesions of the basal ganglia; Parkinson's syndrome, except in the case of dyskinesias due to levodopa treatment; sensitivity to Halop 5 mg; senile patients with pre-existing Parkinson-like symptoms.

Halop 5 mg is a safe neuroleptic. Headache, vertigo, insomnia are the more common side effects encountered. Drowsiness, lethargy, stupor, confusion, restlessness, agitation, anxiety, euphoria and exacerbation of psychotic symptoms including hallucinations also may occur. Dry mouth, blurred vision, urinary retention, heartburn, nausea, vomiting, anorexia, diarrhea and hypersalivation have also been reported.

There is no proven harmful effect in the first trimester, however there have been some reports of limb malfonnations, so the drug is best avoided if possible. The principal hazard in late pregnancy is extrapyramidal adverse effects in the neonate. The drug is excreted only in trace amounts and sedation or extrapyramidal rigidity in the neonate can occur but is rarely a problem.

Halop 5 mg may lower the convulsive threshold and has been reported to trigger seizures in previously controlled known epileptics. When instituting Halop 5 mg therapy in these patients, adequate anticonvulsant medication should be maintained concomitantly. As with other antipsychotic agents, Halop 5 mg should be administered cautiously to patients with severe impairment of liver or kidney function and to patients with known allergies or history of allergies to other neuroleptic drugs. Caution is also advised in patients with pheochromocytoma and conditions predisposing to epilepsy such as alcohol withdrawal and brain damage. Since the drug may have a possible potentiating effect on potent analgesics or hypnotics, caution is recommended when prescribing it to patients who are regularly treated with such drugs.

In general, the symptoms of overdosage would be an exaggeration of known pharmacologic effects and adverse reactions, the most prominent of which would be: severe extrapyramidal reactions, hypotension or sedation.The patient would appear comatose with respiratory depression and hypotension which could be severe enough to produce a shock-like state.

Do not store above 30°C. Keep away from light and out of the reach of children.

Butyrophenone drugs, Drugs used in tremor, tics & related disorder

Halop 5 mg is a butyropherone derivative with antipsychotic properties that has been considered particularly effective in the management of hyperactivity, agitation and mania. Halop 5 mg is an effective neuroleptic and also possesses antiemetic properties. It may also exhibit hypothermic and anorexiant effects and potentiate the action of barbiturates, general anesthetics and other CNS depressant drugs. Halop 5 mg is a quick acting substance and has a duration of action of about 12 hours after one single administration. The optimum daily therapy consists of 2 administrations.

Safety for use in pregnancy and lactation has not been established; do not administer to women of childbearing potential or nursing mothers unless, in the opinion of the physician, the expected benefits of the drug outweigh the potential hazard to the fetus or child. Halop 5 mg is excreted in breast milk.